Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4 T-cell proliferation and attenuate production of inflammatory cytokines: A potential therapy for celiac disease

Mucosal Immunology

Volumn 4, Issue 1, 2011, Pages 112-120

  Huan, J ^a,b   Meza Romero, R ^a,b   Mooney, J L ^a,b   Vandenbark, A A ^a,b,c   Offner, H ^a,b,c   Burrows, G G ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIADIN; HLA DQ2 ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELIAC DISEASE; CELL PROLIFERATION; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SEQUENCE ALIGNMENT;

EID: 78650846041     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2010.44     Document Type: Article

References (52)

1. Tuckova , L. et al. Activation of macrophages by gliadin fragments: isolation and characterization of active peptide. J. Leukocyte Biol. 71 , 625-631 ( 2002 ).
2. Maiuri , L. et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease.[see comment]. Lancet. 362 , 30-37 ( 2003 ).
3. Mamone , G. et al. Identification of a peptide from alpha-gliadin resistant to digestive enzymes: implications for celiac disease. J. Chromatography B: Anal. Technol. Biomed. Life Sci. 855 , 236-241 ( 2007 ).
4. Shan , L. et al. Structural basis for gluten intolerance in celiac sprue. Science 297 , 2275-2279 ( 2002 ).
5. Farrell , R. J. & Kelly , CP. Celiac Sprue. N Engl. J. Med. 346 , 180-188 ( 2002 ).
6. Johnston , S. D. , Watson , R. G. , McMillan , S. A. , Sloan , J. & Love , A. H. Coeliac disease detected by screening is not silent-simply unrecognized. QJM 91 , 853-860 ( 1998 ).
7. Catassi , C. F. E. et al. The coeliac iceberg in Italy: a multicentre antigliadin antibodies screening for coeliac disease in schoolage subjects. Acta Paediatr. Suppl. 412 , 29-35 ( 1996 ).
8. Burrows , G. G. , Chang , J. W. , Bachinger , H. P. , Bourdette , D. N. , Offner , H. & Vandenbark , A. A. Design, engineering and production of functional single-chain T cell receptor ligands. Protein Eng. 12 , 771-778 ( 1999 ).
9. Burrows , G. G. , Bebo , B. F. Jr. , Adlard , K. L. , Vandenbark , A. A. & Offner , H. Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis. J. Immunol. 161 , 5987-5996 ( 1998 ).
10. Burrows , G. G. et al. Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J. Immunol. 167 , 4386-4395 ( 2001 ).
11. Wang , C. et al. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J. Immunol. 171 , 1934-1940 ( 2003 ).
12. Fontenot , A. P. et al. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells. J. Immunol. 177 , 3874-3883 ( 2006 ).
13. Huan , J. et al. MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis. J. Immunol. 180 , 1249-1257 ( 2008 ).
14. Adamus , G. , Burrows , G. G. , Vandenbark , A. A. & Offner , H. Treatment of autoimmune anterior uveitis with recombinant TCR ligands. Invest. Ophthalmol. Vis. Sci. 47 , 2555-2561 ( 2006 ).
15. Sinha , S. et al. Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand. J. Neurosci. 29 , 3816-3823 ( 2009 ).
16. Burrows , G. G. et al. Regulation of encephalitogenic T cells with recombinant TCR ligands. J. Immunol. 164 , 6366-6371 ( 2000 ).
17. Chang , J. W. , Mechling , D. E. , Bachinger , H. P. & Burrows , G. G. Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2. J. Biol. Chem. 276 , 24170-24176 ( 2001 ).
18. Smith , K. J. , Pyrdol , J. , Gauthier , L. , Wiley , D. C. & Wucherpfennig , K. W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188 , 1511-1520 ( 1998 ).
19. Li , Y. , Li , H. , Martin , R. & Mariuzza , R. A. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J. Mol. Biol. 304 , 177-188 ( 2000 ).
20. Brown , J. H. , Jardetzky , T. S. , Gorga , J. C. , Stern , L. J. , Urban , R. G. & Strominger , J. L. Three dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364 , 33 ( 1993 ).
21. Murthy , V. L. & Stern , L. J. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Structure 5 , 1385-1396 ( 1997 ).
22. Fremont , D. H. , Hendrickson , W. A. , Marrack , P. & Kappler , J. Structures of an MHC class II molecule with covalently bound single peptides. Science 272 , 1001 ( 1996 ).
23. Sadegh-Nasseri , S. & McConnell , H. M. A kinetic intermediate in the reaction of an antigenic peptide and I-Ek. Nature 337 , 274-276 ( 1989 ).
24. Sadegh-Nasseri , S. , Natarajan , S. , Chou , C. L. , Hartman , I. Z. , Narayan , K. & Kim , A. Conformational heterogeneity of MHC class II: induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection. Immunol. Res. 47 , 56-64 ( 2010 ).
25. Xia , J. , Sollid , L. M. & Khosla , C. Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2. Biochemistry 44 , 4442-4449 ( 2005 ).
26. Nag , B. , Arimilli , S. , Mukku , P. V. & Astafieva , I. Functionally active recombinant alpha and beta chain-peptide complexes of human major histocompatibility class II molecules. J. Biol. Chem. 271 , 10413-10418 ( 1996 ).
27. Nag , B. , Kendrick , T. , Arimilli , S. , Yu , S. C. & Sriram , S. Soluble MHC II-peptide complexes induce antigen-specific apoptosis in T cells. Cell. Immunol. 170 , 25-33 ( 1996 ).
28. Arimilli , S. , Cardoso , C. , Mukku , P. , Baichwal , V. & Nag , B. Refolding and reconstitution of functionally active complexes of human leukocyte antigen DR2 and myelin basic protein peptide from recombinant alpha and beta polypeptide chains. J. Biol. Chem. 270 , 971-977 ( 1995 ).
29. Kozono , H. , White , J. , Clements , J. , Marrack , P. & Kappler , J. Production of soluble MHC class II proteins with covalently bound single peptides. Nature 369 , 151-154 ( 1994 ).
30. Appel , H. , Gauthier , L. , Pyrdol , J. & Wucherpfennig , K. W. Kinetics of T-cell receptor binding by bivalent HLA-DR.Peptide complexes that activate antigen-specific human T-cells. J. Biol. Chem. 275 , 312-321 ( 2000 ).
31. Appel , H. , Seth , N. P. , Gauthier , L. & Wucherpfennig , K. W. Anergy induction by dimeric TCR ligands. J. Immunol. 166 , 5279-5285 ( 2001 ).
32. Huan , J. et al. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J. Immunol. 172 , 4556-4566 ( 2004 ).
33. Burrows , G. G. Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands. Curr. Drug Targets Inflamm. Allergy 4 , 185-193 ( 2005 ).
34. Vandenbark , A. A. et al. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J. Immunol. 171 , 127-133 ( 2003 ).
35. Rich , C. et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2- transgenic mice. Eur. J. Immunol. 34 , 1251-1261 ( 2004 ).
36. Chou , Y. K. et al. T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice. J. Neurosci. Res. 77 , 670-680 ( 2004 ).
37. Huan , J. Y. et al. Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. J. Chem. Tech. Biotech. 80 , 2-12 ( 2005 ).
38. Chen , G. C. & Yang , J. T. Some hydrodynamic and optical properties of polyribonucleotides. Biophys. Chem. 1 , 62-72 ( 1973 ).
39. Provencher , S. W. & Glockner , J. Estimation of globular protein secondary structure from circular dichroism. Biochemistry 20 , 33-37 ( 1981 ).
40. Huang , Y. H. , Colgrave , M. L. , Daly , N. L. , Keleshian , A. , Martinac , B. & Craik , D. J. The biological activity of the prototypic cyclotide kalata b1 is modulated by the formation of multimeric pores. J. Biol. Chem. 284 , 20699-20707 ( 2009 ).
41. Spits , H. , Keizer , G. , Borst , J. , Terhorst , C. , Hekman , A. & de Vries , J. E. Characterization of monoclonal antibodies against cell surface molecules associated with cytotoxic activity of natural and activated killer cells and cloned CTL lines. Hybridoma 2 , 423-437 ( 1983 ).
42. Viken , H. D. et al. Characterization of an HLA-DQ2-specific monoclonal antibody. Influence of amino acid substitutions in DQ beta 1*0202. Hum. Immunol. 42 , 319-327 ( 1995 ).
43. Johansen , B. H. et al. Binding of peptides to HLA-DQ molecules: peptide binding properties of the disease-associated HLA-DQ(alpha 1*0501, beta 1*0201) molecule. Int. Immunol. 6 , 453-461 ( 1994 ).
44. Ziegler , A. et al. Analysis by sequential immunoprecipitations of the specificities of the monoclonal antibodies TU22,34,35,36,37,39,43,58 and YD1/63.HLK directed against human HLA class II antigens. Immunobiology 171 , 77-92 ( 1986 ).
45. Viken , H. D. , Thorsby , E. & Gaudernack , G. Characterization and epitope mapping of four HLA class II reactive mouse monoclonal antibodies using transfected L cells and human cells transfected with mutants of DQB1*0302. Tissue Antigens 45 , 250-257 ( 1995 ).
46. Molberg , O. , McAdam , S. N. & Sollid , L. M. Role of tissue transglutaminase in celiac disease. J Pediatric Gastroenterol. Nutr. 30 , 232-240 ( 2000 ).
47. Qiao , S. W. , Bergseng , E. , Molberg , O. , Jung , G. , Fleckenstein , B. & Sollid , L. M. Refining the rules of gliadin T cell epitope binding to the diseaseassociated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation. J. Immunol. 175 , 254-261 ( 2005 ).
48. Qiao , S.- W. et al. Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease. J. Immunol. 174 , 1657-1663 ( 2005 ).
49. Tollefsen , S. et al. HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease. J. Clin. Invest. 116 , 2226-2236 ( 2006 ).
50. Compton , L. A. & Johnson , W. C. Jr. Analysis of protein circular dichroism spectra for secondary structure using a simple matrix multiplication. Anal. Biochem. 155 , 155-167 ( 1986 ).
51. Kim , C.- Y. , Quarsten , H. , Bergseng , E. , Khosla , C. & Sollid , L. M. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. PNAS 101 , 4175-4179 ( 2004 ).
52. Bohm , G. , Muhr , R. & Jaenicke , R. Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng. 5 , 191-195 ( 1992 ).